Effects of ertugliflozin monotherapy or combination therapy on glycaemic control, body weight, and blood pressure in patients with type 2 diabetes: a pooled analysis

被引：0
|
作者：
Lauring, B. [1 ]
Liu, J. [1 ]
Tarasenko, L. [2 ]
Terra, S. G. [3 ]
Huyck, S. [1 ]
Wu, L. [1 ]
Pong, A. [1 ]
Calle, R. A. [4 ]
Gallo, S. [5 ]
Darekar, A. [6 ]
Mancuso, J. P. [7 ]
机构：
[1] Merck & Co Inc, Kenilworth, NJ USA
[2] Pfizer Inc, New York, NY USA
[3] Pfizer Inc, Andover, MA USA
[4] Pfizer Inc, Cambridge, MA USA
[5] Pfizer Pharma GmbH, Berlin, Germany
[6] Pfizer Ltd, Walton Oaks, England
[7] Pfizer Inc, Groton, CT 06340 USA
来源：
DIABETOLOGIA | 2018年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
628
引用
收藏
页码：S305 / S305
页数：1
相关论文
共 50 条
  • [21] Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET) (vol 20, pg 520, 2017)
    Rosenstock, Julio
    Frias, Juan
    Pall, Denes
    Charbonnel, Bernard
    Pascu, Raluca
    Saur, Didier
    Darekar, Amanda
    Huyck, Susan
    Shi, Harry
    Lauring, Brett
    Terra, Steven G.
    DIABETES OBESITY & METABOLISM, 2018, 20 (11): : 2708 - 2708
  • [22] Effect of orforglipron versus placebo and dulaglutide on glycaemic control and body weight in patients with type 2 diabetes
    Mather, K. J.
    Frias, J. P.
    Hsia, S.
    Eyde, S.
    Liu, R.
    Ma, X.
    Konig, M.
    Kazda, C.
    Pratt, E.
    Haupt, A.
    Robins, D.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S151 - S152
  • [23] Study of metabolic control, body weight, body mass index and blood pressure in patients with Type 2 diabetes with insulin resistance with intensified insulin therapy
    Kumar, Anil
    Iska, Reddy
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 79 : S68 - S68
  • [24] The Effects of Depression on Glycaemic Control in Patients with Type 2 Diabetes
    Zhu, Jasmine J.
    Hare, David L.
    Jerums, George
    Stewart, Andrew G.
    Macisaac, Richard J.
    DIABETES, 2014, 63 : A592 - A592
  • [25] The effect of dietary fiber on glycaemic control in patients with type 2 diabetes on metformin monotherapy
    Tramontana, F.
    Maddaloni, E.
    Greci, S.
    Defeudis, G.
    Strollo, R.
    Pozzilli, P.
    Napoli, N.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S105 - S105
  • [26] The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial
    Hanefeld, M
    Sachse, G
    DIABETES OBESITY & METABOLISM, 2002, 4 (06): : 415 - 423
  • [27] A Pooled Analysis of the Efficacy and Safety of Saxagliptin as Monotherapy in Patients with Type 2 Diabetes
    Hirshberg, Boaz
    Bryzinski, Brian
    Xu, John
    Iqbal, Nayyar
    JOURNAL OF DIABETES & METABOLISM, 2015, 6 (04)
  • [28] Efficacy and Safety of Saxagliptin as Monotherapy in Patients with Type 2 Diabetes: A Pooled Analysis
    Hirshberg, Boaz
    Bryzinski, Brian
    Xu, John
    Monyak, John
    Iqbal, Nayyar
    DIABETES, 2014, 63 : A610 - A610
  • [29] Triple combination therapy with sitagliptin, metformin, and rosiglitazone improves glycaemic control in patients with type 2 diabetes
    Ferreira, J. C. Arjona
    Dobs, A.
    Goldstein, B. J.
    Wieczorek, L.
    Golm, G.
    Davies, M. J.
    Williams-Herman, D.
    Kaufman, K. D.
    Amatruda, J. M.
    DIABETOLOGIA, 2008, 51 : S365 - S365
  • [30] The contribution of metformin to glycaemic control in patients with Type 2 diabetes mellitus receiving combination therapy with insulin
    Tong, PC
    Chow, CC
    Jorgensen, LN
    Cockram, CS
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2002, 57 (02) : 93 - 98
12345